USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
News|Articles|November 2, 2003
- Pharmaceutical Technology-11-02-2003
- Volume 27
- Issue 11
Aseptic Processing Guidelines and Innovative Engineering Boost Appeal of Barrier Isolators
Author(s)Maribel Rios
FDA's aseptic processing draft guidance and the industry's state-of-the-art isolator technologies prepare manufacturers for the next generation of contamination control solutions.
Advertisement
Articles in this issue
about 23 years ago
FDA Will Drive Changes for Contract Businessabout 23 years ago
In the Spotlight--Decemberabout 23 years ago
Novemember 2003about 23 years ago
FDA Seeks Risk-Based Inspection Programabout 23 years ago
Routine Sample Size for a Retest Procedureabout 23 years ago
November 2003about 23 years ago
Clearing Regulatory Hurdlesabout 23 years ago
Improving Protein Capture for Transgenic Drug ProcessingAdvertisement
Related to this article
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
Onshoring pharmaceutical manufacturing can be made more practical by collaborating with CDMOs that have gray space, supported by strong relationships with used equipment dealers and OEMs.
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
2
Why Drug Shortages Average 5+ Years: PharmTech Explained
3
What the First Factor XIa Approval Means for Developers
4
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
5